ScreenerHero

DMRADamora Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · damoratx.com
30.82USD-4.99%Mkt Cap: 1.90B $P/E: —

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclona…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.90B $
Enterprise Value1.46B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-209.84M $
Revenue/Share—
Last Price30.82 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.15
PEG—
EV/EBITDA-15.19
EV/Revenue—
P/S—
P/B4.85
EPS (TTM)-0.26
EPS (Forward)-2.14
52W Range
30.1420% of range33.56
52W High33.56 USD
52W Low30.14 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-87.29%
ROA-80.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.73M $
CapEx (TTM)—
FCF Margin—
FCF Yield-0.84%
Net Debt-540.52M $
Net Debt/EBITDA5.61
Balance Sheet
Debt/Equity0.00
Current Ratio19.73
Quick Ratio19.65
Book Value/Sh6.254 USD
Cash/Share8.755 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateAug 30, 2024
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)44.67 USD
Upside (mean)+44.9%
Target Range40.00 USD – 51.00 USD
$40.00+44.9% to mean$51.00
# Analysts9
Ownership
Shares Out.61.74M
Float41.40M
Insiders7.60%
Institutions105.63%
Short Interest
Short Ratio9.7d
Short % Float9.25%
Short % Out.7.93%
Shares Short4.89M
Short (prev mo.)3.57M
Technical
SMA 5027.90 (+10.5%)
SMA 20025.29 (+21.9%)
Beta1.48
S&P 52W Chg18.16%
Avg Vol (30d)332.92K
Avg Vol (10d)301.29K
Technical Indicators
RSI (14)54.0
MACD0.7439
MACD Signal0.8013
MACD Hist.-0.0574
BB Upper32.30 USD
BB Middle30.19 USD
BB Lower28.07 USD
BB Width14.02%
ATR (14)1.909 USD
Vol Ratio (20d)0.42x